scholarly journals Body Mass Index and Mortality in Individuals With Type 1 Diabetes

2019 ◽  
Vol 104 (11) ◽  
pp. 5195-5204 ◽  
Author(s):  
Emma H Dahlström ◽  
Niina Sandholm ◽  
Carol M Forsblom ◽  
Lena M Thorn ◽  
Fanny J Jansson ◽  
...  

Abstract Context The relationship between body mass index (BMI) and mortality may differ between patients with type 1 diabetes and the general population; it is not known which clinical characteristics modify the relationship. Objective Our aim was to assess the relationship between BMI and mortality and the interaction with clinically meaningful factors. Design, Setting, and Participants This prospective study included 5836 individuals with type 1 diabetes from the FinnDiane study. Main Outcome Measure and Methods We retrieved death data for all participants on 31 December 2015. We estimated the effect of BMI on the risk of mortality using a Cox proportional hazards model with BMI as a restricted cubic spline as well as effect modification by adding interaction terms to the spline. Results During a median of 13.7 years, 876 individuals died. The relationship between baseline BMI and all-cause mortality was reverse J-shaped. When analyses were restricted to those with normal albumin excretion rate, the relationship was U-shaped. The nadir BMI (BMI with the lowest mortality) was in the normal weight region (24.3 to 24.8 kg/m2); however, among individuals with diabetic nephropathy, the nadir BMI was in the overweight region (25.9 to 26.1 kg/m2). Diabetic nephropathy, diabetes-onset age, and sex modified the relationship between BMI and mortality (Pinteraction < 0.05). Conclusions Normal weight is optimal for individuals with type 1 diabetes to delay mortality, whereas underweight might be an indication of underlying complications. Maintaining normal weight may translate into reduced risk of mortality in type 1 diabetes, particularly for individuals of male sex, later diabetes-onset age, and normal albumin excretion rate.

2007 ◽  
Vol 156 (1) ◽  
pp. 83-90 ◽  
Author(s):  
Peter Hovind ◽  
Steven Lamberts ◽  
Wim Hop ◽  
Jaap Deinum ◽  
Lise Tarnow ◽  
...  

Objective: Derangements of the GH–IGF-I axis have been associated with microalbuminuria (MA) in type 1 diabetes. The aim of this study was to investigate whether an IGF-I gene promoter polymorphism influenced the development of persistent MA in type 1 diabetes. Design: A prospective follow-up study of a cohort of 277 patients with newly diagnosed type 1 diabetes consecutively enrolled between September 1979 and August 1984. Methods: Urinary albumin excretion rate over 24 h was measured in each patient at least once a year. Persistent MA was defined as a urinary albumin excretion rate between 30 and 300 mg/24 h. Results: During a median follow-up of 18.0 years (range 1.0–21.5), 79 of 277 patients developed persistent MA. IGF-I gene genotype was available for 216 subjects; in 73% of the subjects, the wild-type genotype of this IGF-I gene polymorphism was present, while 27% had the variant type. At baseline, there were no differences in IGF-I levels and HbA1c values between subjects with the wild type and subjects with variant type. By Kaplan–Meier analysis, subjects with the variant type of this polymorphism had during follow-up a higher risk of development of MA compared subjects with the wild type (P = 0.03). Conclusions: Subjects with the variant type of an IGF-I gene polymorphism had a significantly increased risk of developing MA. This risk was not mediated through changes in circulating IGF-I levels. Our study suggests that in type 1 diabetes, this IGF-I gene polymorphism is a risk factor of MA.


2019 ◽  
Vol 11 (12) ◽  
pp. 1002-1004
Author(s):  
Julia Seyfarth ◽  
Osei Sarfo‐Kantanka ◽  
Joachim Rosenbauer ◽  
Richard O. Phillips ◽  
Marc Jacobsen

1991 ◽  
Vol 11 (3) ◽  
pp. 189-193 ◽  
Author(s):  
Satish K. Garg ◽  
H. Peter Chase ◽  
William E. Jackson ◽  
Sherrie Harris ◽  
Guillermo Marshall ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document